{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T15:42:57Z","timestamp":1773157377309,"version":"3.50.1"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2012,1,11]],"date-time":"2012-01-11T00:00:00Z","timestamp":1326240000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0030042","type":"journal-article","created":{"date-parts":[[2012,1,11]],"date-time":"2012-01-11T21:56:52Z","timestamp":1326319012000},"page":"e30042","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":53,"title":["BRCAness Profile of Sporadic Ovarian Cancer Predicts Disease Recurrence"],"prefix":"10.1371","volume":"7","author":[{"given":"Weiya Z.","family":"Wysham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulette","family":"Mhawech-Fauceglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Hays","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanna","family":"Syriac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tijana","family":"Skrepnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nupur","family":"Pande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen","family":"Hoatlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanja","family":"Pejovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2012,1,11]]},"reference":[{"issue":"4","key":"ref1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics 2009.","volume":"59","author":"A Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"issue":"22","key":"ref2","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1200\/JCO.2010.28.5791","article-title":"Personalizing therapy for ovarian cancer: BRCAness and beyond.","volume":"28","author":"RC Bast","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/cncr.11310","article-title":"Improved survival in women with BRCA associated ovarian carcinoma.","volume":"97","author":"I Cass","year":"2003","journal-title":"Cancer"},{"issue":"24","key":"ref4","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","article-title":"Cancer of the ovary.","volume":"351","author":"SA Cannistra","year":"2004","journal-title":"N Engl J Med"},{"issue":"34","key":"ref5","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1200\/JCO.2008.16.1703","article-title":"\u201cBRCAness\u201d syndrome in ovarian cancer: A case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.","volume":"26","author":"DS Tan","year":"2008","journal-title":"J Clin Oncol"},{"issue":"6\u20137","key":"ref6","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/emmm.200900044","article-title":"Converting cancer mutations into therapeutic opportunities.","volume":"1","author":"T O'Brien","year":"2009","journal-title":"EMBO Mol Med"},{"key":"ref7","first-page":"197","article-title":"The role of poly adenosisne diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions.","volume":"7","author":"F Chioh","year":"2011","journal-title":"Asia-Pacific JCO"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1200\/JCO.2009.27.5719","article-title":"Gene Expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.","volume":"28","author":"PA Kontationopoulos","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.","volume":"361","author":"PC Fong","year":"2009","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"277s","DOI":"10.1200\/jco.2009.27.15_suppl.5500","article-title":"Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA deficient advanced ovarian cancer.","volume":"27","author":"MW Audeh","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9737","key":"ref11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.","volume":"376","author":"A Tutt","year":"2010","journal-title":"Lancet"},{"key":"ref12","article-title":"Histological typing of ovarian tumors.","author":"F Serov S","year":"1973"},{"issue":"7","key":"ref13","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/nm0798-844","article-title":"Tissue microarrays for high-throughput molecular profiling of tumor specimens.","volume":"4","author":"J Kononen","year":"1998","journal-title":"Nat Med"},{"key":"ref14","article-title":"The statistical analysis of failure time data (2<sup>nd<\/sup> edition).","author":"J Kalbfleisch","year":"2002"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1200\/JCO.2008.16.1703","article-title":"\u201cBRCAness\u201d syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.","volume":"26","author":"DS Tan","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1200\/JCO.2009.27.2997","article-title":"Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.","volume":"28","author":"BT Hennessy","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"ref17","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nm852","article-title":"Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors.","volume":"9","author":"T Taniguchi","year":"2003","journal-title":"Nat Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"9017","DOI":"10.1158\/0008-5472.CAN-06-0222","article-title":"Cytogenetic instability in ovarian epithelial cells from women at risk of ovarian cancer.","volume":"66","author":"T Pejovic","year":"2006","journal-title":"Cancer Res"},{"issue":"5","key":"ref19","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1172\/JCI31245","article-title":"Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated.","volume":"117","author":"RD Kennedy","year":"2007","journal-title":"J Clin Invest"},{"issue":"9","key":"ref20","first-page":"3445","article-title":"Sporadic breast carcinomas with somatic BRCA1 gene deletions share genotype\/phenotype features with familial breast carcinomas.","volume":"30","author":"K Rhiem","year":"2010","journal-title":"Anticancer Res"},{"issue":"53","key":"ref21","doi-asserted-by":"crossref","first-page":"53ra75","DOI":"10.1126\/scitranslmed.3001538","article-title":"PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.","volume":"2","author":"KJ Dedes","year":"2010","journal-title":"Sci Transl Med"},{"issue":"3","key":"ref22","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.cell.2008.04.013","article-title":"Tenets of PTEN tumor suppression.","volume":"133","author":"L Salmena","year":"2008","journal-title":"Cell"},{"issue":"2","key":"ref23","first-page":"147","article-title":"Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.","volume":"26","author":"H Brustmann","year":"2007","journal-title":"Int J Gynecol Pathol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1504\/IJBRA.2011.039166","article-title":"A structural bioinformatics approach to explore the interactions of P53 and BRCA1 gene products on ovarian and breast cancer.","volume":"7","author":"S Parija","year":"2011","journal-title":"Int J Bioinform Res Appl"},{"issue":"2","key":"ref25","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/path.2744","article-title":"The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas.","volume":"2010 Oct, 222","author":"M K\u00f6bel","year":"2010","journal-title":"J Pathol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1600-0412.2011.01121.x","article-title":"Identification of BRCA-1 deficient ovarian cancers.","volume":"90","author":"A-B Skytte","year":"2011","journal-title":"ACTA Ostet Gynecol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/6029","article-title":"Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinoma.","volume":"21","author":"CA Wilson","year":"1999","journal-title":"Nat genet"},{"key":"ref28","first-page":"621","article-title":"BRCA1 Gene expression in breast cancer: A correlative study between real-time RT-PCR and immunohistochemistry.","volume":"53","author":"Al-Mulla","year":"2005"},{"key":"ref29","article-title":"Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study.","author":"JI Weberpals","year":"2011","journal-title":"Ann Oncol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"suppl; abstr 5005","DOI":"10.1200\/jco.2011.29.15_suppl.5005","article-title":"Aphase II trial of iniparib (BSI-201) in combination with gemcitibine\/carboplatin (GC) in patients with platinum-resistant recurrent ovarian cancer.","volume":"29","author":"MJ Birrer","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1158\/1535-7163.MCT-05-0493","article-title":"Chemosensitization to cisplatin by inhibitors of the Fanconi anemia\/BRCA pathway.","volume":"5","author":"D Chirnomas","year":"2006","journal-title":"Mol Cancer Ther 2006"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0030042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T20:24:29Z","timestamp":1640463869000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0030042"}},"subtitle":[],"editor":[{"given":"Jun","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2012,1,11]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2012,1,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0030042","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,11]]}}}